MAIL ONLINE: Amgen drug extends survival in some inoperable colon cancers

Press/Media: Research

Release date: 5/6/2022

Media coverage

TitleAmgen drug extends survival in some inoperable colon cancers
Media name/outletMail Online
Media typeWeb
Country/TerritoryUnited Kingdom
Date5/06/22
DescriptionJune 5 (Reuters) - The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Amgen drug extends survival for some advanced colon cancers

Amgen Inc's drug Vectibix led to "the longest survival ever reported" in a major trial for patients with inoperable advanced cancer originating on the left side of the colon whose tumors did not have RAS gene mutations, researchers reported on Sunday at ASCO 2022 https://meetings.asco.org/2022-asco-annual-meeting/14416?presentation=208990#208990.

Amgen's monoclonal antibody, known chemically as panitumumab, belongs to a class of drugs called EGFR inhibitors. The standard treatment in many countries, however, is an anti-VEGF antibody like Roche's Avastin, which means many patients with inoperable metastatic cancer may not have been getting the most effective treatment.

https://www.ibtimes.com/amgen-drug-extends-survival-some-inoperable-colon-cancers-3530544

https://www.usnews.com/news/top-news/articles/2022-06-05/amgen-drug-extends-survival-in-some-inoperable-colon-cancers
URLhttps://www.dailymail.co.uk/wires/reuters/article-10886525/CANCER-RESEARCH-Amgen-drug-extends-survival-inoperable-colon-cancers.html
PersonsMartin Mccabe